story of the week
Th2 IL-4/IL-13 Dual Blockade With Dupilumab Is Linked to Some Emergent Th17 Type Diseases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Investigative Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Th2 IL-4/IL-13 dual blockade with Dupilumab is linked to some Emergent Th17 type Diseases including seronegative arthritis, enthesitis/enthesopathy, but not humoral autoimmune diseases
J Invest Dermatol 2022 Apr 05;[EPub Ahead of Print], C Bridgewood, M Wittmann, T Macleod, A Watad, D Newton, K Bhan, H Amital, G Damiani, S Giryes, NL Bragazzi, D McGonagleFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.